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 Introduction 
 In 1990, the Lewy body variant of Alzheimer’s disease 
(AD)  [1] , also termed senile dementia of Lewy body type 
 [2] or dementia with Lewy bodies (DLB)  [3] , was de-
scribed as a distinct neuropathological and clinical form 
of dementia in the elderly. Autopsy studies have shown 
that in 15–25% of elderly patients with dementia, Lewy 
bodies (LBs) are found in the cortex and brainstem in ad-
dition to various degrees of Alzheimer-type pathology. 
According to these studies, DLB may be the second most 
common cause of dementia after AD  [1, 2, 4–6] . 
 As noted in the initial descriptions of the condition, 
patients with DLB share many clinical features with typ-
ical AD including age, family history, history of onset, 
symptoms, duration of disease, mental status and degree 
of brain atrophy  [7] . Symptoms that distinguish DLB 
from AD without Lewy body pathology are dispropor-
tional impairment of attention, executive function and 
visuospatial performance as well as mild extrapyramidal 
fi ndings  [1] . In studies on patients who met clinical and 
pathological criteria for AD, however, no consistent as-
sociation has been found between the presence of LBs and 
the frequency of these clinical features  [3] . 
 In addition to progressive dementia, the clinical con-
sensus criteria  [7] emphasize fl uctuation of attention and 
alertness, recurrent visual hallucinations and spontane-
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 Abstract 
 The objective of the study was to identify clinical features 
that distinguish patients with dementia with Lewy bod-
ies (DLB), who were classifi ed as Alzheimer’s disease 
(AD) patients, from patients with AD. We examined a 
group of 27 patients from our memory clinic, originally 
diagnosed with AD, of whom 6 were postmortem found 
to have DLB. For the present study, we compared cogni-
tive, noncognitive and neurological symptoms between 
the two groups. We found that there were no differences 
on ratings of dementia and scales for activities of daily 
living. Patients with DLB performed better on the MMSE 
and the memory subtest of the CAMCOG, but there was 
no difference in any other cognitive domain. Further-
more, genetic risk factors, including family history of de-
mentia or allele frequency of the apolipoprotein   4, did 
not discriminate between the two groups, and there 
were no differences on CCT scans. Taken together, our 
fi ndings suggest that Lewy body pathology may be pres-
ent in patients who do not show the typical clinical fea-
tures which distinguish DLB from AD. 
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ous motor features of Parkinsonism. Impairment of 
memory may be absent at early stages. Using these crite-
ria, the sensitivity of the clinical diagnosis is 78%, and the 
specifi city is 64% as compared with neuropathological 
fi ndings  [8] . This is consistent with the fi nding that two 
thirds of patients with pathologically confi rmed DLB 
have less than two core clinical features  [8] . 
 Here, we report on a small group of patients who ful-
fi lled clinical criteria for AD  [9] but were identifi ed as 
having DLB at postmortem examination. The study 
was designed to determine whether classifi cation of 
DLB as AD might have been avoided if distinguishing 
features had been observed, or whether there is a vari-
ant of DLB that cannot be separated from AD on clin-
ical grounds. 
 Methods 
 Patients 
 From 1988 to 1992, we conducted a prospective study which 
was designed to investigate the natural course and possible subtypes 
of AD  [10] . A total of 90 patients were enrolled and re-examined 
at 12-month intervals for up to 3 years. All patients underwent a 
thorough diagnostic evaluation, which included psychiatric inter-
view, physical examination, laboratory screening, cranial comput-
ed tomography and apolipoprotein E genotyping  [11] . 
 Clinical Assessments and Diagnosis 
 The clinical documentation included information on age, age at 
onset, years of education at school and family history of dementia. 
Impairment of cognitive function was assessed using the cognitive 
section (CAMCOG) of the Cambridge Mental Disorders of the El-
derly Examination (CAMDEX)  [12] , which incorporates the Mini-
Mental State Examination (MMSE). Out of 8 subscales of this stan-
dardized interview, 5 were considered in the present study (orien-
tation, language, memory, praxis and perception). The CAMDEX 
protocol also provides information on activities of daily living 
(ADL) obtained from an informant (orientation in and around the 
home, performing household chores, handling money, eating, 
dressing, bladder and bowel control). For the present analysis, these 
variables were combined into an ADL score, higher values indi-
cated greater impairment. Furthermore, informant ratings of non-
cognitive symptoms were taken from the CAMDEX standardized 
interview (hallucinations, paranoid ideation and fl uctuating atten-
tion). These symptoms were rated as present or absent. 
 Neurological signs were documented in a standardized form. Of 
10 signs recorded, gait disorder and increased muscle tone were 
selected and combined in a neurological score  for the present anal-
ysis. Tremor was recorded as part of the CAMDEX documentation. 
Severity of dementia was rated on the Dementia Scale (DS)  [13] , 
the Global Deterioration Scale (GDS)  [14] and the Clinical Demen-
tia Rating (CDR)  [15] . 
 Based on this extensive information, a consensus diagnosis of 
AD was made by two experienced clinicians according to ICD-10 
research criteria  [9] . A probable AD was diagnosed using the 
NINCDS-ADRDA criteria  [16] . In 1996, Rasmussen et al.  [17] 
showed that these diagnoses are 90% accurate. At the time of study, 
diagnostic criteria for DLB were not available, since they were only 
introduced in 1992  [18] . Patients who had marked neurological 
symptoms or a history of cerebrovascular accidents were not in-
cluded. 
 Neuropathological Evaluation and Diagnostic Criteria 
 Brains were fi xed in 4% formalin in phosphate-buffered saline 
for at least 14 days. Representative blocks were embedded in par-
affi n and processed for routine histology. Sections (4   m) were cut 
and stained with hematoxylin and eosin, according to Gallyas and 
Bielschowsky silver impregnation. Immunohistochemistry was 
performed with anti-tau antibody AT8 (dilution 1:  100; Innogenet-
ics, Ghent, Belgium), anti-synuclein antibody 15G7 (dilution 1:  10), 
anti-  amyloid peptide antibody (1:  100; Dako, Glostrup, Den-
mark) and anti-ubiquitin antiserum (1:  300; Dako). Antibody bind-
ing was detected using the Dako alkaline phosphatase/anti-alkaline 
phosphatase system and neufuchsin as chromogen. 
 The pathological diagnosis was made using established interna-
tional criteria. Alzheimer’s pathology was classifi ed using the 
CERAD pathologic criteria, based on semiquantitative analysis of 
neuritic plaques  [19] , as well as the Braak and Braak classifi cation, 
based on the distribution of neurofi brillary tangles and neuropil 
threads  [20] . 
 Distribution and frequency of LBs were evaluated according to 
consensus guidelines for diagnosing DLB  [7] . The number of LBs 
was counted in the therein defi ned brain regions using   -synuclein 
immunohistochemistry and was converted into scores of 0 (no 
LBs), 1 (1–4 LBs) and 2 ( 1 5 LBs) for each area. Based on the total 
score, cases were divided into 3 subtypes: brainstem predominant, 
limbic and neocortical. 
 The neuropathological diagnosis   of DLB was made if LBs were 
present in the diagnostic areas, irrespective of the severity   of AD 
pathology. 
 The diagnosis of dementia lacking distinctive histopathology 
(DLDH) and corticobasal degeneration (CBD) was made according 
to McKhann et al.  [21] and Dickson et al.  [22] , respectively. 
 Postmortem diagnosis was attempted in as many patients as 
possible. Of the 66 patients who had died between 1988 and 1997, 
autopsy was obtained in 27 cases. The clinical diagnosis of AD was 
confi rmed in 19 patients, 6 patients had additional Lewy body pa-
thology and were classifi ed as DLB. Two patients showed no AD-
related pathology and were diagnosed as DLDH or CBD. Neuro-
pathological information is shown in  table 1 . 
 Apolipoprotein E Genotyping 
 The apolipoprotein E genotype was determined according to the 
procedures described previously  [23] . 
 Data Analysis 
 Statistical analysis was performed using the Statistical Package 
for the Social Sciences  [24] , version 10.0. Demographic data, sever-
ity ratings (MMSE, DS, GDS, CDR), CAMCOG subscores, ADL, 
BEH and neurological scores were compared between AD and DLB 
patients applying   2  tests for frequencies and linear regression
analysis for group means, controlling for age at onset and educa-
tion. 
 The Alzheimer Variant of Lewy Body 
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 Results 
 Demographic Data 
 Patients with AD and DLB did not differ signifi cantly 
regarding gender distribution and years of education. 
However, DLB patients were signifi cantly older than AD 
patients ( table 2 ). A family history of dementia was found 
in 26% in AD and 33% in DLB cases ( table 3 ). 
 Apolipoprotein E Genotype 
 Of the 19 patients with AD, 14 were carriers of the 
apolipoprotein E   4 allele, whereas only 3 of 6 patients 
with DLB were   4 positive. The   4 allele frequency was 
0.42 in the AD group and 0.50 in the DLB group. This 
difference was not statistically signifi cant (p = 0.12)
( table 3 ). 
 Cranial Computed Tomography 
 Brain atrophy was seen in 13 out of 17 patients with 
AD (76%) for whom CT scans were available and in 5 
patients with DLB (83%). This difference did not reach 
statistical signifi cance ( table 3 ). 
 Severity of Dementia 
 Although they were signifi cantly older, patients with 
DLB achieved a higher cognitive performance on the 
MMSE than patients with AD ( table 4 ). Due to the small 
sample size, the difference of 4 points on the scale was 
not of statistical signifi cance. General severity of demen-
tia, as assessed using the DS, GDS or CDR, was not dif-
ferent between the two diagnostic groups. 
 Cognitive Ability 
 There was no statistically signifi cant difference on any 
CAMCOG subscale between the two diagnostic groups 
( table 4 ). Fluctuation of attention was not observed in 
either group. 
 Noncognitive Symptoms 
 Hallucinations were present in 2 out of 6 patients with 
DLB and in 1 out of 19 patients with AD. This difference 
fell short of reaching statistical signifi cance ( table 4 ). 
 ADL and Neurological Symptoms 
 There were no statistically signifi cant differences be-
tween the diagnostic groups with regard to these symp-
toms ( table 5 ). Furthermore, tremor was absent in both 
groups. 
 Table 1. Neuropathological information 
Case Sex Age Diag-
nosis
CERAD Braak and
Braak stage
LB pathol-
ogy
1 F 72 AD C VI none
2 M 74 AD C V none
3 F 68 AD C VI none
4 F 73 AD C VI none
5 F 78 AD C VI none
6 M 83 AD C VI none
7 M 80 AD C VI none
8 F 70 AD C V none
9 M 63 AD C V none
10 F 70 AD C V none
11 F 71 AD C VI none
12 F 72 AD C VI none
13 F 89 AD C IV none
14 M 81 AD C V none
15 F 83 AD C V none
16 F 81 AD C V none
17 F 84 AD C V none
18 F 63 AD C VI none
19 F 70 AD C VI none
20 F 79 DLB C V neocortical
21 F 85 DLB C V–VI neocortical
22 F 80 DLB C V–VI neocortical
23 F 79 DLB C V neocortical
24 F 85 DLB C V neocortical
25 F 80 DLB C V–VI neocortical
26 F 78 DLDH 0 I none
27 M 69 CBD B II none
 
 
 Table 2. Demographic data 
Variable AD (n = 19) DLB (n = 6) p value
Females:males 15:4 5:1 0.82
Family history, yes:no 5:14 2:4 0.74
Education, years 9.581.7 9.081.8 0.51
Age at onset, years 66.287.9 74.483.7 0.03
Figures for education and age at onset are expressed as mean 8 
SD. 
 
 
 Table 3. Genetic variables and cranial computed tomography 
(CCT) fi ndings 
Variable AD DLB p value
ApoE 4 allele frequency 0.42 0.50 0.12
Brain atrophy on CCT 0.77 0.83 0.73
Family history of dementia 0.26 0.33 0.74
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 Discussion 
 The present study refers to a highly selected group of 
patients who were referred to a university memory clinic 
for diagnostic evaluation. All patients included in this 
study fulfi lled ICD-10 research criteria for AD  [9] . At 
postmortem examination, AD was confi rmed in 19 of 
these patients, but 6 subjects were found to have DLB. 
All cases classifi ed as DLB had severe Alzheimer-related 
pathology (CERAD C and Braak and Braak stage V–VI) 
in addition to signifi cant Lewy body counts in diagnosti-
cally important areas. In the present paper, we compare 
cognitive, noncognitive and neurological symptoms be-
tween the two groups at the time of enrollment. The ob-
jective of the study was to identify clinical features that 
distinguish patients with DLB who were classifi ed as AD 
from patients with AD. 
 Patients with DLB were signifi cantly older at onset of 
symptoms than AD patients. On ratings of dementia se-
verity, the two groups were identical, the majority of pa-
tients showing a moderate degree of intellectual impair-
ment. Furthermore, there was no difference in the ability 
to carry out ADL. On the MMSE, however, patients with 
DLB had higher average scores than patients with AD, 
suggesting that their cognitive performance was better. 
This is consistent with a nonsignifi cantly higher score on 
the memory subtest of the CAMCOG. There was no dif-
ference between the groups in any other cognitive do-
main. This indicates that the profi le of cognitive abilities 
may not be useful for the differentiation between AD and 
DLB. 
 Even though present clinical diagnostic criteria for 
DLB were not available at the time of our study, we feel 
confi dent that the clinical assessment covered all the im-
portant early signs of DLB. Typical symptoms, such as 
fl uctuating attention, visual hallucinations and tremor, 
are part of the CAMDEX interview, and neurological 
symptoms with focus on additional features of Parkin-
sonism were recorded in a standardized form. Parkinso-
nian symptoms, in particular tremor, gait disorder and 
increased muscle tone, were absent in both groups. An-
other major feature of DLB  [7] was absent in the DLB 
group, namely fl uctuating attention. Furthermore, hallu-
cinations were only present in one third of these individ-
uals. There have been previous comparisons between AD 
and DLB in patients with neuropathologically confi rmed 
diagnosis, which also did not fi nd any differences regard-
ing cognitive impairment, hallucinations and fl uctuating 
attention  [25] . A recent study comes to the similar con-
clusion that patients with signifi cant tangle pathology 
who are pathologically assigned a DLB diagnosis were 
clinically indistinguishable from AD  [26] . On the other 
hand, there are authors who report that visual hallucina-
tions are more common in DLB  [27, 28] and suggest that 
the distinction between AD and DLB may be improved 
by greater emphasis on hallucinations  [29] . Furthermore, 
some studies found a signifi cantly higher impairment of 
attention in patients with DLB  [30] and more fl uctuations 
of attention compared with patients who suffered from 
AD  [31, 32] . Fluctuating attention also has a signifi cant 
impact on ADL  [33] . 
 Genetic risk factors also did not discriminate between 
the groups; approximately one third of the DLB and AD 
patients had a positive family history of dementia, and 
the apolipoprotein E   4 allele frequency was elevated 
above control values to a similar extent in both groups. 
This fi nding is consistent with several other studies which 
also found no difference in the   4 allele frequency be-
tween AD and DLB  [34–36] . In addition, the frequency 
of atrophic changes seen on CT scans was not different 
 Table 4. Psychopathological symptoms 
Variable AD (n = 19) DLB (n = 6) p value
MMSE 14.984.9 18.883.2 0.06
DS 12.284.8 14.784.3 0.09
GDS, 4/5/6 3/13/3  1/4/1 1.00
CDR, 1/2/3 8/10/1  3/3/0 0.82
Orientation 3.181.9 5.083.4 0.94
Language 17.585.7 18.787.4 0.82
Memory 3.683.3 7.583.7 0.10
Praxis 6.782.6 6.283.1 0.67
Perception 4.683.2 4.382.1 0.89
Delusions, no/yes 17/2 4/2 0.23
Hallucinations, no/yes 19/1 4/2 0.13
ADL 7.084.4 8.084.2 0.66
Figures are expressed as mean 8 SD, except for GDS, CDR, 
delusions and hallucinations.
 
 
 Table 5. ADL and neurological symptoms  
Variable AD
(n = 19)
DLB
(n = 6)
p value
ADL 7.084.4 8.084.2 0.66
Neurological symptoms, no/yes 17/2 6/0 0.41
Figures for ADL are expressed as mean 8 SD.
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between the two groups. Previous studies have found
a strong correlation between DLB and occipital defi cits 
in cerebral perfusion  [37] and glucose metabolism  [38, 
39] . However, as was the case in the present study, no 
changes in occipital brain structure were seen  [40] and 
the CT or MRI fi ndings did not differ between the two 
types of dementia  [41] . 
 Taken together, our fi ndings suggest that Lewy body 
pathology may be present in patients who do not show 
any of the clinical features which distinguish DLB from 
AD according to present diagnostic criteria. This is con-
sistent with the sensitivity of these criteria of 78%, which 
has been found in clinicopathological correlations  [8] . Di-
agnostic sensitivity may possibly be improved by includ-
ing more sensitive tests of attention and executive ability 
in the neuropsychological evaluation and by using the full 
range of diagnostic possibilities, such as positron emis-
sion tomography  [39, 42, 43] , brain perfusion scintigra-
phy  [44] and liquor markers  [45–47] . 
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